Yes, Saxenda is a GLP-1 receptor agonist. Its active ingredient, liraglutide, is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone your body naturally produces to regulate appetite and blood sugar. Saxenda is specifically approved for weight management, not diabetes, which is what sets it apart from other medications that use the same ingredient.
How Saxenda Works as a GLP-1 Drug
GLP-1 is a hormone released by your gut after you eat. It signals your brain that you’re full, slows down how fast food leaves your stomach, and helps regulate blood sugar by boosting insulin and dialing back glucagon (a hormone that raises blood sugar). The problem is that natural GLP-1 breaks down in your body within minutes.
Saxenda mimics this hormone but lasts much longer, giving it time to produce sustained effects. In the brain, it acts on regions that control appetite, influencing the release of neurotransmitters and peptides that regulate hunger and energy expenditure. In the rest of the body, it delays gastric emptying so you feel full longer after meals, enhances insulin secretion, and reduces glucagon release. The combined result is that you eat less and your blood sugar stays more stable.
Saxenda vs. Victoza: Same Ingredient, Different Purpose
This is a point of confusion for many people. Saxenda and Victoza both contain liraglutide, but they are approved for completely different conditions and prescribed at different doses.
- Victoza is approved for type 2 diabetes management, with a maximum dose of 1.8 mg per day. It is not approved for weight loss on its own.
- Saxenda is approved for chronic weight management, with a maximum dose of 3 mg per day. It is explicitly not indicated for the treatment of type 2 diabetes.
The higher dose in Saxenda reflects what clinical trials found was needed to produce meaningful weight loss. You cannot simply use Victoza at a higher dose as a substitute, because the two products have different prescribing guidelines and FDA approvals.
Who Qualifies for Saxenda
Saxenda is approved as an add-on to a reduced-calorie diet and increased physical activity. For adults, you need a BMI of 30 or higher (which falls into the obese category), or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. For adolescents aged 12 and older, the threshold is a BMI that corresponds to 30 or above by adult standards, and a body weight over 60 kg (about 132 pounds).
How Much Weight to Expect
In the SCALE Diabetes clinical trial, participants taking 3 mg of liraglutide daily lost an average of 6% of their body weight over 56 weeks. Those on 1.8 mg lost 4.7%, while the placebo group lost 2%. For someone who weighs 220 pounds, a 6% loss translates to about 13 pounds over roughly a year. These numbers reflect averages, so some people lose more and some less. Results also depend heavily on diet and activity changes made alongside the medication.
The Dose Escalation Schedule
Saxenda is a daily injection you give yourself under the skin, typically in the abdomen, thigh, or upper arm. You don’t start at the full dose. Instead, the dose increases gradually over five weeks to reduce the chance of side effects, particularly nausea.
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5 and beyond: 3 mg daily (the maintenance dose)
This stepwise approach gives your body time to adjust. Gastrointestinal symptoms like nausea are the most common reason people struggle in the early weeks, and a gradual ramp-up helps minimize that.
Common Side Effects
The most frequently reported side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Nausea tends to be worst during the dose escalation period and often improves as your body adjusts. Eating smaller meals and avoiding high-fat foods can help. Some people also experience headaches, fatigue, or dizziness, particularly in the first few weeks.
Important Safety Concerns
Saxenda carries a boxed warning related to thyroid tumors. In animal studies, liraglutide caused thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC). It’s not confirmed whether this risk applies to humans, but as a precaution, Saxenda is contraindicated if you or anyone in your family has a history of MTC or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you notice a lump in your neck, difficulty swallowing, hoarseness, or shortness of breath while taking Saxenda, those are symptoms worth bringing to your doctor’s attention promptly.
How Saxenda Compares to Newer GLP-1 Drugs
Saxenda was one of the earlier GLP-1 receptor agonists approved for weight management. Newer drugs in the same class, such as semaglutide (sold as Wegovy for weight loss), tend to produce greater average weight loss and are dosed weekly rather than daily. Semaglutide also works on GLP-1 receptors but has a longer half-life, which is why it only needs one injection per week. The newer dual-action drugs that target both GLP-1 and GIP receptors (like tirzepatide, sold as Zepbound) have shown even higher average weight loss in trials. Saxenda remains a valid option, but it is no longer considered the most potent GLP-1 medication available for weight management.